Ferro Milena, Macchia Gabriella, Pezzulla Donato, Cilla Savino, Romano Carmela, Ferro Marica, Boccardi Mariangela, Bonome Paolo, Picardi Vincenzo, Buwenge Milly, Morganti Alessio G, Deodato Francesco
Radiation Oncology Unit, Responsible Research Hospital, Campobasso 86100, Italy.
Medical Physics Unit, Responsible Research Hospital, Campobasso 86100, Italy.
Br J Radiol. 2024 Jun 18;97(1159):1295-1301. doi: 10.1093/bjr/tqae099.
Stereotactic body radiotherapy (SBRT) and/or single fraction stereotactic body radiosurgery (SRS) are effective treatment options for the treatment of oligometastatic disease of lymph nodes. Despite the encouraging local control rate, progression-free survival remains unfair due to relapses that might occur in the same district or at other sites. The recurrence pattern analysis after nodal local ablative RT (laRT) in oligometastatic patients is presented in this study.
The pattern of failure of patients with nodal metastases who were recruited and treated with SBRT in the Destroy-1 or SRS in the Destroy-2 trials was investigated in this single-institution, retrospective analysis. The different relapsed sites following laRT were recorded.
Data on 190 patients who received SBRT or SRS on 269 nodal lesions were reviewed. A relapse rate of 57.2% (154 out of 269 nodal lesions) was registered. The pattern of failure was distant in 88 (57.4%) and loco-regional in 66 (42.6%) patients, respectively. The most frequent primary malignancies among patients experiencing loco-regional failure were genitourinary and gynaecological cancers. Furthermore, the predominant site of loco-regional relapse (62%) was the pelvic area. Only 26% of locoregional relapses occurred contra laterally, with 74% occurring ipsilaterally.
The recurrence rates after laRT for nodal disease were more frequent in distant regions compared to locoregional sites. The most common scenarios for locoregional relapse appear to be genitourinary cancer and the pelvic site. In addition, recurrences often occur in the same nodal station or in a nodal station contiguous to the irradiated nodal site.
Local ablative radiotherapy is an effective treatment in managing nodal oligometastasis. Despite the high local control rate, the progression free survival remains dismal with recurrences that can occur both loco-regionally or at distance. To understand the pattern of failure could aid the physicians to choose the best treatment strategy. This is the first study that reports the recurrence pattern of a significant number of nodal lesions treated with laRT.
立体定向体部放疗(SBRT)和/或单次分割立体定向体部放射外科治疗(SRS)是治疗淋巴结寡转移疾病的有效选择。尽管局部控制率令人鼓舞,但由于可能在同一区域或其他部位发生复发,无进展生存期仍不尽人意。本研究展示了寡转移患者接受淋巴结局部消融放疗(laRT)后的复发模式分析。
在这项单机构回顾性分析中,研究了在Destroy-1试验中接受SBRT治疗或在Destroy-2试验中接受SRS治疗的有淋巴结转移患者的失败模式。记录laRT后不同的复发部位。
回顾了190例患者269个淋巴结病灶接受SBRT或SRS治疗的数据。登记的复发率为57.2%(269个淋巴结病灶中的154个)。失败模式分别为远处复发88例(57.4%)和局部区域复发66例(42.6%)。局部区域失败患者中最常见的原发性恶性肿瘤是泌尿生殖系统和妇科癌症。此外,局部区域复发的主要部位(62%)是盆腔区域。仅26%的局部区域复发发生在对侧,74%发生在同侧。
与局部区域部位相比,laRT治疗淋巴结疾病后远处区域的复发率更高。局部区域复发最常见的情况似乎是泌尿生殖系统癌症和盆腔部位。此外,复发常发生在同一淋巴结区域或与照射淋巴结部位相邻的淋巴结区域。
局部消融放疗是治疗淋巴结寡转移的有效方法。尽管局部控制率高,但无进展生存期仍不容乐观,复发可发生在局部区域或远处。了解失败模式有助于医生选择最佳治疗策略。这是第一项报告大量接受laRT治疗的淋巴结病灶复发模式的研究。